Suvretta Capital Management, LLC holds a diversified book of 88 stocks worth $3.7B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Veradermics Inc and trimmed Apellis Pharmaceuticals Inc. Their largest long position is Arcutis Biotherapeutics Inc at 8% of the equity book. They also disclosed $227.6M in put options (a bearish bet), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1569064/holdings"
Use Arkolith to show SUVRETTA CAPITAL MANAGEMENT, LLC's latest holdings, largest changes, and filing provenance.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
95% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Arcutis Biotherapeutics Inc COM | $290.4M | 12.33M | 7.9% | ▲+3.0% Added · +363K sh | |
| 2 | Veradermics Inc COMMON STOCK | $263.3M | 4.17M | 7.1% | ▲New New position | |
| 3 | Palvella Therapeutics Inc Ne COM | $143.8M | 1.15M | 3.9% | ▲+29% Added · +261K sh | |
| 4 | Apellis Pharmaceuticals Inc COM | $141.5M | 3.52M | 3.8% | ▼−15% Reduced · −621K sh | |
| 5 | Legend Biotech Corp SPONSORED ADS | $137.1M | 7.58M | 3.7% | ▲+15% Added · +972K sh | |
| 6 | Benitec Biopharma Inc COM NEW | $123.0M | 11.55M | 3.3% | —Held | |
| 7 | Capricor Therapeutics Inc COM NEW | $116.1M | 3.82M | 3.1% | ▲+114% Added · +2.0M sh | |
| 8 | Immatics N.V SHS | $110.1M | 11.19M | 3.0% | —Held | |
| 9 | Arcus Biosciences Inc COM | $108.7M | 5.03M | 2.9% | ▼−3.0% Reduced · −158K sh | |
| 10 | Eyepoint Inc COM NEW | $106.9M | 8.30M | 2.9% | ▲+6.0% Added · +469K sh | |
| 11 | Arrivent Biopharma Inc COM | $101.5M | 4.40M | 2.8% | ▲+7.2% Added · +295K sh | |
| 12 | Taiwan Semiconductor Manufac SPONSORED ADS | $100.9M | 298.7K | 2.7% | ▲+10% Added · +27K sh | |
| 13 | Nvidia Corporation COM | $100.2M | 574.7K | 2.7% | ▲+8.2% Added · +44K sh | |
| 14 | Meta Platforms Inc CL A | $97.1M | 169.7K | 2.6% | ▲+0.4% Added · +638 sh | |
| 15 | Kalvista Pharmaceuticals Inc COM | $96.0M | 4.77M | 2.6% | —Held | |
| 16 | Ge Aerospace COM NEW | $88.0M | 310.3K | 2.4% | —Held | |
| 17 | Biohaven Ltd COM | $87.0M | 10.29M | 2.4% | —Held | |
| 18 | Sysco Corp COM | $82.7M | 1.16M | 2.2% | ▲+7.0% Added · +75K sh | |
| 19 | MGM Resorts International COM | $79.9M | 2.16M | 2.2% | ▲+80% Added · +957K sh | |
| 20 | Compass Therapeutics Inc COM | $75.7M | 14.31M | 2.1% | ▲+0.9% Added · +125K sh | |
| 21 | Home Depot Inc COM | $72.9M | 221.6K | 2.0% | ▼−8.0% Reduced · −19K sh | |
| 22 | Kura Oncology Inc COM | $69.7M | 8.58M | 1.9% | —Held | |
| 23 | Monte Rosa Therapeutics Inc COM | $69.5M | 4.23M | 1.9% | ▲+26% Added · +867K sh | |
| 24 | Bank America Corp COM | $63.1M | 1.30M | 1.7% | ▼−15% Reduced · −222K sh | |
| 25 | Erasca Inc COM | $55.6M | 3.43M | 1.5% | ▼−76% Reduced · −11.1M sh | |
| 26 | Capital One Finl Corp COM | $55.2M | 302.4K | 1.5% | ▲+76% Added · +130K sh | |
| 27 | Zura Bio Ltd CLASS A ORD SHS | $53.9M | 9.07M | 1.5% | ▲+63% Added · +3.5M sh | |
| 28 | Amazon Com Inc COM | $52.9M | 254.0K | 1.4% | ▼−37% Reduced · −152K sh | |
| 29 | Advanced Micro Devices Inc COM | $52.3M | 257.2K | 1.4% | ▼−34% Reduced · −132K sh | |
| 30 | Fulcrum Therapeutics Inc COM | $50.3M | 6.56M | 1.4% | —Held | |
| 31 | Vulcan Matls Co COM | $49.4M | 181.6K | 1.3% | ▲New New position | |
| 32 | Ferguson Enterprises Inc COMMON STOCK NEW | $49.4M | 211.9K | 1.3% | ▲+33% Added · +53K sh | |
| 33 | Apollo Global Mgmt Inc COM | $43.2M | 387.7K | 1.2% | ▼−29% Reduced · −155K sh | |
| 34 | Mineralys Therapeutics Inc COM | $41.7M | 1.54M | 1.1% | —Held | |
| 35 | Crinetics Pharmaceuticals In COM | $37.9M | 1.04M | 1.0% | ▲New New position | |
| 36 | Contineum Therapeutics Inc CL A | $37.1M | 2.84M | 1.0% | —Held | |
| 37 | US Foods Hldg Corp COM | $36.5M | 396.0K | 1.0% | ▲New New position | |
| 38 | Performance Food Group Co COM | $33.1M | 386.9K | 0.9% | ▲New New position | |
| 39 | Replimune Group Inc COM | $32.3M | 4.22M | 0.9% | ▲117× Added · +4.2M sh | |
| 40 | Advisorshares TR PURE US CANNABIS | $32.1M | 9.05M | 0.9% | ▲+4.3% Added · +377K sh | |
| 41 | Aura Biosciences Inc COM | $29.3M | 4.37M | 0.8% | —Held | |
| 42 | Unitedhealth Group Inc COM | $27.2M | 100.6K | 0.7% | ▼−9.6% Reduced · −11K sh | |
| 43 | Prokidney Corp SHS CL A | $22.1M | 12.34M | 0.6% | —Held | |
| 44 | Life Time Group Holdings Inc COMMON STOCK | $13.7M | 510.3K | 0.4% | ▲New New position | |
| 45 | Whitehawk Therapeutics Inc COM | $12.8M | 3.70M | 0.3% | —Held | |
| 46 | Abeona Therapeutics Inc COM NEW | $12.0M | 2.68M | 0.3% | —Held | |
| 47 | Wingstop Inc COM | $9.2M | 59.5K | 0.3% | ▲New New position | |
| 48 | Molecular Partners AG ADS | $8.8M | 2.22M | 0.2% | —Held | |
| 49 | Boston Scientific Corp COM | $7.8M | 123.9K | 0.2% | ▼−65% Reduced · −230K sh | |
| 50 | Lexeo Therapeutics Inc COM | $7.2M | 1.25M | 0.2% | —Held |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| PUT · bearish | SS SPDR S&P 500 ETF TRUST-USSPY | $227.6M | 350K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 89 | $3.9B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 93 | $4.9B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 93 | $3.9B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 98 | $3.3B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 100 | $2.7B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 96 | $2.9B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 98 | $3.1B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 98 | $2.7B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 15, 2024 | 101 | $2.7B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 88 | $2.2B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 14, 2023 | 87 | $1.9B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 100 | $1.9B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 95 | $2.4B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 89 | $2.4B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 73 | $2.4B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 89 | $2.6B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 87 | $3.3B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 95 | $5.2B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 16, 2021 | 106 | $5.9B | 13F-HR/A |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 122 | $6.7B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 106 | $6.8B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 106 | $7.0B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.